TG Therapeutics Inc (NASDAQ: TGTX)’s stock price has increased by 7.62 compared to its previous closing price of 22.83. However, the company has seen a 12.50% increase in its stock price over the last five trading sessions. investors.com reported 2024-10-11 that None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Is It Worth Investing in TG Therapeutics Inc (NASDAQ: TGTX) Right Now?
TG Therapeutics Inc (NASDAQ: TGTX) has a price-to-earnings ratio that is above its average at 40.94x. The stock has a 36-month beta value of 2.20. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TGTX is 137.98M, and at present, short sellers hold a 24.93% of that float. On October 16, 2024, the average trading volume of TGTX was 3.56M shares.
TGTX’s Market Performance
The stock of TG Therapeutics Inc (TGTX) has seen a 12.50% increase in the past week, with a -1.29% drop in the past month, and a 11.28% gain in the past quarter. The volatility ratio for the week is 4.96%, and the volatility levels for the past 30 days are at 4.64% for TGTX. The simple moving average for the past 20 days is 6.43% for TGTX’s stock, with a 35.08% simple moving average for the past 200 days.
Analysts’ Opinion of TGTX
Many brokerage firms have already submitted their reports for TGTX stocks, with Goldman repeating the rating for TGTX by listing it as a “Neutral.” The predicted price for TGTX in the upcoming period, according to Goldman is $12 based on the research report published on August 02, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see TGTX reach a price target of $40, previously predicting the price at $55. The rating they have provided for TGTX stocks is “Buy” according to the report published on June 26th, 2023.
BofA Securities gave a rating of “Underperform” to TGTX, setting the target price at $5 in the report published on May 20th of the previous year.
TGTX Trading at 7.32% from the 50-Day Moving Average
After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.97% of loss for the given period.
Volatility was left at 4.64%, however, over the last 30 days, the volatility rate increased by 4.96%, as shares sank -2.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +42.77% upper at present.
During the last 5 trading sessions, TGTX rose by +12.50%, which changed the moving average for the period of 200-days by +39.44% in comparison to the 20-day moving average, which settled at $23.09. In addition, TG Therapeutics Inc saw 43.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TGTX starting from Lonial Sagar, who sale 16,348 shares at the price of $16.87 back on Jun 20 ’24. After this action, Lonial Sagar now owns 105,195 shares of TG Therapeutics Inc, valued at $275,791 using the latest closing price.
Lonial Sagar, the Director of TG Therapeutics Inc, sale 9,585 shares at $16.39 during a trade that took place back on Jun 17 ’24, which means that Lonial Sagar is holding 99,293 shares at $157,098 based on the most recent closing price.
Stock Fundamentals for TGTX
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.93 for the gross margin
The net margin for TG Therapeutics Inc stands at 0.28. The total capital return value is set at 0.35. Equity return is now at value 87.78, with 30.76 for asset returns.
Based on TG Therapeutics Inc (TGTX), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at 0.65. The debt to equity ratio resting at 0.58. The interest coverage ratio of the stock is 8.21.
Currently, EBITDA for the company is 21.06 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 11.06. The receivables turnover for the company is 4.15for trailing twelve months and the total asset turnover is 0.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.58.
Conclusion
To sum up, TG Therapeutics Inc (TGTX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
